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Role of TRAIL and the pro-apoptotic Bcl-2 homolog
Bim in acetaminophen-induced liver damage
A Badmann1, A Keough2, T Kaufmann3, P Bouillet4, T Brunner*,1,5,6 and N Corazza*,1,6
Acetaminophen (N-acetyl-para-aminophenol (APAP), paracetamol) is a commonly used analgesic and antipyretic agent.
Although considered safe at therapeutic doses, accidental or intentional overdose causes acute liver failure characterized by
centrilobular hepatic necrosis with high morbidity and mortality. Although many molecular aspects of APAP-induced cell death
have been described, no conclusive mechanism has been proposed. We recently identified TNF-related apoptosis-inducing
ligand (TRAIL) and c-Jun kinase (JNK)-dependent activation of the pro-apoptotic Bcl-2 homolog Bim as an important apoptosis
amplification pathway in hepatocytes. In this study, we, thus, investigated the role of TRAIL, c-JNK and Bim in APAP-induced
liver damage. Our results demonstrate that TRAIL strongly synergizes with APAP in inducing cell death in hepatocyte-like cells
lines and primary hepatocyte. Furthermore, we found that APAP strongly induces the expression of Bim in a c-JNK-dependent
manner. Consequently, TRAIL- or Bim-deficient mice were substantially protected from APAP-induced liver damage. This study
identifies the TRAIL-JNK-Bim axis as a novel target in the treatment of APAP-induced liver damage and substantiates its general
role in hepatocyte death.
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Acetaminophen (N-acetyl-para-aminophenol (APAP), para-
cetamol) is a commonly used analgesic and antipyretic
agent.1 Although considered safe at therapeutic doses,
accidental or intentional overdose causes acute liver failure
characterized by centrilobular hepatic necrosis with high
morbidity and mortality.2 Despite substantial effort in the past
to investigate the processes involved in APAP-induced liver
toxicity, the exact molecular and biochemical mechanisms
remain incompletely understood. There is a general con-
sensus that the formation of a toxic electrophilic metabolite by
the P450 system,N-acetyl-p-benzoquinone imine (NAPQI), is
a prerequisite for hepatocyte injury.3 NAPQI is usually
detoxified by glutathione in the liver. However, APAP over-
dose depletes hepatic glutathione so much that NAPQI
covalently binds to cellular proteins leading to mitochondrial
dysfunction. Thus, APAP inhibits mitochondrial respiration
and causes a decrease in ATP levels in liver cells.4 More
recently, in vivo study provided evidence for the formation of
peroxynitrite in the mitochondria and the induction of
mitochondrial damage.5 It is still under debate whether
covalent binding to critical protein targets or oxidative stress
as a consequence of mitochondrial glutathione depletion is
the promoting factor of hepatocyte death. Most probably,
however, liver cell death after APAP overdose is the
consequence of interplay between multiple events. Further-
more, glutathione depletion and covalent binding to cellular
proteins seems not to be sufficient to induce mitochondrial
dysfunction resulting in liver failure. In experimental animal
models, the progression and severity of APAP-induced liver
toxicity is not only associated with the triggering of the
membrane permeability transition and the collapse of mito-
chondrial membrane potential, but depends on the interplay of
other death-inducing signals, both within and outside the
hepatocytes.
The death mechanism(s) of APAP-induced liver damage is
still a matter of debate. Clearly, typical signs of both necrotic
and apoptotic cell death can be observed. There is also a
significant overlap between events normally associated with
apoptosis and APAP-induced cell death. For instance,
mitochondrial events generally linked to apoptosis have been
observed in APAP-induced hepatic cell death, including the
proteolytic processing of the pro-apoptotic Bcl-2 family
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member Bid, the translocation of Bid and Bax to the
mitochondria and the release of cytochrome c.6 In agreement
with the role of Bcl-2 family members in APAP-induced
hepatocyte death is that mitochondrial Bax translocation
accelerates DNA fragmentation and cell death in APAP-
induced liver damage.7 Moreover, a critical role of the stress
kinase c-Jun N-terminal kinase (Jun kinase, JNK) has been
demonstrated in both APAP-induced liver damage8 and other
forms of hepatocyte apoptosis.9–11 Thus, APAP treatment
leads to JNK activation, and administration of JNK inhibitors
have a protective effect on APAP-induced hepatocyte death
and associated liver damage. Similarly, a role of JNK has
been postulated in TNFa12 and Fas ligand-mediated hepato-
cyte apoptosis and hepatitis.9
JNK is likely involved in death ligand-induced hepatocyte
apoptosis by the phosphorylation and activation of down-
stream apoptosis effector molecules. In agreement with this
notion, we have recently shown that JNK phosphorylates the
pro-apoptotic Bcl-2 homolog Bim, and that JNK-activated
Bim critically regulates Fas-induced hepatocyte apoptosis.9
Interestingly, we have seen that Fas-induced hepatocyte
apoptosis is synergistically enhanced by the TNF-related
apoptosis-inducing ligand (TRAIL) receptor signaling pathway
via TRAIL-induced JNK activation and Bim phosphorylation.
Similarly, Kaufmann et al.13 demonstrated that D-galactosa-
mine/lipopolysaccharide-induced hepatitis in mice, proceed-
ing via TNF-a-mediated hepatocyte apoptosis, also depends
on JNK and Bim. Finally, a beneficial effect of JNK inhibition
has also been observed in hepatic ischemia-reperfusion
injury.14
Given the critical role of JNK and Bim in various forms of
hepatocyte apoptosis, and the similarity between APAP-
induced liver damage and hepatitis mediated by the
apoptosis pathway, we explored in this study the role of death
receptor-induced JNK and associated Bim activation in
APAP-induced liver damage. We here demonstrate that
APAP-induced hepatocyte death is enhanced by the TRAIL
signaling pathway. Similarly, APAP-induced liver damage is
reduced in TRAIL-deficient mice. Treatment of mice, isolated
hepatocytes or hepatoma cell lines with APAP results in an
increase in Bim expression, which is dependent on APAP-
induced JNK activation. Finally, we demonstrate that
APAP-induced liver damage is significantly attenuated in
Bim-deficient mice. These findings demonstrate a novel role
of the BH3-only protein Bim in APAP-induced liver damage,
and further accentuate the role of JNK and Bim in hepatocyte
cell death.
Results
APAP-induced death is synergistically enhanced by
TRAIL. We have previously shown that TRAIL synergisti-
cally enhances Fas-induced apoptosis in hepatocytes in a
JNK-Bim-dependent manner.9 We thus tested whether
APAP-induced hepatocyte cell death is also enhanced by
treatment the cells with TRAIL. Isolated primary human
hepatocytes (hHep) were stimulated with increasing doses of
APAP, in the presence or absence of low doses of TRAIL.
Figure 1a illustrates that APAP alone failed to induce
significant cell death in primary hHeps. Similarly, TRAIL
alone, at 3 and 30ng/ml, did not promote any death-inducing
activities. However, combined treatment of cells with TRAIL
and increasing doses of APAP synergistically induced cell
death in primary hepatocytes. Similar results were also
confirmed in the hepatoma cell line HepG2 and immortalized
human hepatocytes (IHHs) (Figures 1b and c). The
synergistic induction of cell death in IHH was paralleled by
increased caspase 3 activity (DEVDase activity) and
phosphatidyl serine externalization. These data confirm that
TRAIL synergistically enhances APAP-induced cell death in
hepatocytes and hepatocyte-like cells in vitro.
Figure 1 TRAIL synergizes with APAP in inducing cell death. Human
hepatocytes (hHep) (a), the hepatoma cell line HepG2 (b) or immortalized human
hepatocytes (IHH) (c) were preincubated with buffer control or increasing
concentrations of TRAIL, prior stimulation with different doses of APAP. Cell death
was assessed by MTT assay (a–c) in primary hepatocytes, HepG2 and IHH cells, by
DEVD cleavage assay (d) or Annexin V staining (e) in control IHH cells or IHH cells
treated with 10 mM APAP, 30 ng TRAIL or the combination thereof, respectively.
Mean values±S.D. of triplicates are shown for MTT and DEVDase assays, which
were repeated three times, yielding similar results. A typical experiment out of two is
shown for Annexin V staining
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We next investigated the relevance of TRAIL-mediated
enhancement of APAP-induced cell death also in vivo. Wild-
type (WT) C57Bl/6 mice or TRAIL-deficient mice were treated
with overdose of APAP (400mg/kg body weight) and liver
damage was assessed 5 h later by tissue histology and serum
transaminases. Figure 2a illustrates that APAP induced
severe tissue destruction with large areas of damaged and
necrotic hepatocytes in WT animals. In contrast, histological
alterations were reduced in APAP-treated TRAIL-deficient
mice. Reduced liver damage of TRAIL-deficient mice com-
pared with WT animals after APAP treatment was also
confirmed by transaminase activity in the sera. Although
treatment of WT animals with APAP resulted in a strong
increase in serum ALT activity, reduced levels were seen in
APAP-treated TRAIL-deficient mice. These data indicate that
endogenous TRAIL contributes to APAP-induced hepatocyte
death and liver damage also in vivo.
APAP induces expression of Bim. Our previous studies
have demonstrated an important role of Bim in hepatocyte
apoptosis.9 We thus investigated whether APAP or TRAIL
would affect Bim expression in primary hepatocytes and
hepatocyte-like cell lines. Analysis of Bim expression by
western blot revealed that treatment of primary hHep
(Figure 3a), HepG2 (Figure 3b) and IHH cells (Figure 3c)
with APAP resulted in a strong induction of Bim expression.
In contrast, no increase in Bim levels were seen in primary
hHeps and HepG2 cells after treatment with TRAIL, and only
a slight induction was observed in IHH cells. Combined
treatment of cells (HepG2 and IHH), with TRAIL and APAP
did not further increase expression of Bim. In agreement with
these in vitro data, increased Bim protein levels were also
observed in liver samples from APAP-treated mice
(Figure 3d).
To define in more detail whether APAP induces an
increased Bim protein levels either by stabilization of the
protein or by promoting Bim gene expression, we analyzed
Bim mRNA expression after treatment with APAP and/or
TRAIL by quantitative RT-PCR. TRAIL was found to be an
Figure 2 TRAIL is required for efficient APAP-induced liver damage in vivo. Wild type (WT) or TRAIL-deficient mice (TRAIL/) were treated with PBS as control or
APAP (400 mg/kg body weight), and liver damage was analyzed by histology (a) and transaminase levels (AST) in serum (b) after 5 h. Pooled experimental data from 8 to 12
mice per group are shown
Figure 3 APAP induces Bim protein expression. Human hepatocytes (a),
HepG2 (b) or IHH (c) cells were treated with APAP, TRAIL or both for 6 h, and Bim
protein expression was analyzed by western blot. (d) Liver samples of PBS- or
APAP-treated wild-type mice were analyzed for the expression of Bim by western
blot. JNK or tubulin was used to normalize protein loadings
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inefficient inducer of Bim mRNA expression in primary
hepatocytes and IHH cells, and moderately induced Bim
expression in HepG2 cells. In contrast, APAP strongly
promoted Bim mRNA expression in all cells tested (Figures
4a–c). No synergy between APAP and TRAIL in promoting
Bim mRNA expression was detected. Bim mRNA levels were
also significantly increased in the liver of APAP-treated WT
mice compared with PBS-treated control mice (Figure 4d).
APAP induces Bim promoter activity in a JNK-
dependent manner. JNK has been previously implicated
in the transcriptional control of Bim expression via an AP-1-
dependent pathway. Furthermore, JNK activity has been
shown to participate in APAP-induced liver disease.8,15 In
accordance with these reports, we demonstrated that APAP
alone induced a robust JNK activation as measured by the
detection of phospho-JNK by western blot (Figure 5a).
APAP-induced JNK activation was comparable to that
induced by phorbol 12-myristate 13-acetate used as
positive control. To investigate the role of JNK in APAP-
induced Bim gene expression we used a luciferase reporter
construct containing 0.8 kb of the Bim proximal promoter.16
Although this Bim promoter construct was constitutively
active in control-treated cells, relatively low concentrations of
APAP (2.5mM) induced the Bim reporter construct
(Figure 5b). Higher concentrations further induced Bim
promoter activity by about fourfold above levels of
unstimulated cells (Figures 5b and c). Inhibition of JNK, by
the pharmacological inhibitor, resulted in a strong inhibition of
Figure 4 APAP induces Bim transcription. Human hepatocytes (a), HepG2
(b) or IHH (c) cells were treated with with 10 mM APAP, 30 ng TRAIL or the
combination thereof for 6 h, and Bim expression was analyzed by quantitative
RT-PCR. (d) Wild-type mice were treated with PBS or APAP, and Bim expression
was analyzed in liver samples by quantitative RT-PCR after 5 h. GAPDH was used
to normalize Bim expression levels. Mean values±S.D. of triplicates are shown for
fold induction of mRNA levels. Pooled data from 6 to 7 mice per group are shown.
*P¼ 0.011 (unpaired Student’s t-test)
Figure 5 APAP-induced Bim transcription is JNK- and Foxo3a-dependent.
(a) IHH cells were stimulated with APAP (10 mM) or, as positive control, phorbol 12-
myristate 13-acetate (30 ng/ml) and phospo-JNK and tubulin protein levels were
analyzed at different time points by western blot. (b) IHH cells were transfected with
the wild-type (WT) Bim reporter construct, pre-treated with JNK V inhibitor (10mM)
and stimulated with APAP (10 mM) or phorbol 12-myristate 13-acetate (30 ng/ml).
(c) Similarly, IHH cells were transfected with the WT Bim reporter construct,
pretreated with different concentrations of the JNK inhibitor V and stimulated
with APAP (10 mM). Luciferase activity was measured and normalized to
b-galactosidase. (d) IHH were pretreated with JNK inhibitor V and stimulated with
APAP (10 mM). Bim mRNA expression was measured by quantitative RT-PCR
(6 h). (e) IHH cells were treated as described above and Bim were analyzed at
different time points by western blot. (f) IHH cells were transfected with empty vector
(pGL2), the wild-type (Bim WT) or the Foxo3a mutant Bim reporter constructs (Bim
Foxo3a), and stimulated with APAP (10 mM) for 6 h. Luciferase activity was
measured and normalized to b-galactosidase activity. Mean values±S.D. of
triplicates are shown for relative luciferase units and fold induction of mRNA levels.
The experiments have been repeated three times, yielding similar results
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APAP-induced Bim promoter activity (Figures 5b and c), Bim
mRNA expression (Figure 5d) and Bim protein expression
(Figure 5e).
These findings indicate that JNK has a role in APAP-
induced Bim expression in liver cells. Foxo3a has also been
reported to be involved in the regulation of Bim expression and
associated apoptosis in various forms of liver disease.17 In
agreement with this proposed role of Foxo3a, we also found
that APAP-induced Bim promoter activity in IHH cells was
reduced when Foxo3a binding sites were mutated in the Bim
promoter, indicating that APAP-induced Bim expression is
also regulated in part by the transcription factor Foxo3a
(Figure 5f).
APAP-induced liver damage is Bim-dependent. Given
the potent Bim-inducing activity of APAP in vivo and in vitro,
we analyzed the role of Bim in APAP-induced liver damage
in vivo. Wild-type and Bim-deficient C57Bl/6 mice were
treated with an overdose of APAP (400mg/kg body weight)
and liver damage was analyzed by histological alterations
and serum transaminase levels 5 h later. While in WT
animals APAP treatment resulted in the extensive hepatic
cell death and large necrotic lesions described earlier
(Figure 6a), tissue damage was substantially reduced in
Bim-deficient mice, indicating that Bim is an important
determinant of APAP-induced liver damage. These findings
were confirmed when analyzing serum transaminase levels.
While APAP treatment of WT mice resulted in a strong
increase of ALT levels, significantly reduced levels were
seen in drug-treated Bim-deficient mice. These findings
support a critical role of Bim in APAP-induced hepatocyte
death and liver damage.
Discussion
Owing to its unique position, the liver is a frequent target of
damage induced by drugs, xenobiotics and oxidative stress.
Although the liver has a sophisticated detoxification system,
overdoses of hepatotoxic agents may eventually lead to liver
cell death, acute liver damage and liver failure. APAP is a
well-characterized liver-damaging substance, whose hepato-
toxic activities have been widely studied. Nevertheless, so far
investigations have failed to identify a single critical pathway
involved in APAP-induced liver damage, and rather suggest a
multitude of factors and signaling events leading to the
observed effects in vitro and in vivo. Thus, APAP-induced liver
damage is the interplay of several distinct death mechanisms.
Our study, identifying TRAIL, JNK and Bim as critical
elements in APAP-induced hepatocyte cell death in vitro and
in vivo, has added new elements into this scheme of
underlying mechanisms of APAP-induced liver damage. It
also provides interesting new links between known pathways
of APAP-induced hepatocyte death and other forms of
hepatitis. In particular, JNK has been previously associated
with APAP-induced and other forms of hepatocyte death.8,10
Our findings that APAP induces JNK activation, and that JNK
activity is critical for APAP-induced Bim expression further
supports an important role of this stress kinase pathway in the
regulation of liver cell death. Recent findings suggest that
APAP-induced JNK activation may be mediated via an ASK1-
dependent manner.18 Interestingly, we have also previously
demonstrated a regulatory role of JNK activation in death
ligand-induced hepatocyte apoptosis. JNK was found to be
critical for the phosphorylation and activation of Bim in
response to Fas and TNF receptor activation.9,13 Similarly,
we describe here a critical role of JNK in APAP-induced Bim
induction. In contrast to our previous results on death
receptor-induced hepatitis, our present data suggest that
APAP-induced JNK activation may be rather involved in
activation of the Bim promoter and induction of Bim expres-
sion. APAP treatment induced a strong increase in Bim
promoter activity, mRNA and protein expression, which was
significantly inhibited by a JNK inhibitor. Although phosphor-
ylation of Bim has been observed in some circumstances, the
induction of Bim expression appears to be the main pathway
by which JNK is involved in APAP-induced hepatocyte death.
Our study also substantiates a relevant role for Bim in
APAP-induced liver damage, and further supports a major
function of this Bcl-2 homolog protein in hepatocyte cell
death in general. Although Fas- and TNF receptor-induced
Figure 6 Bim is required for efficient APAP-induced liver damage in vivo. Wild-type (WT) or Bim-deficient mice (Bim/) were treated with PBS as control or 400 mg/kg
body weight APAP, and liver damage was analyzed by histology (a) and transaminase levels (AST) in serum (b). Pooled data from 10 to 12 mice per group are shown.
**P¼ 0.0047 (unpaired Student’s t-test)
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hepatocyte cell death, a prototypical type II cell, has been
suggested to depend on caspase 8-mediated cleavage of the
BH3-only protein Bid to tBid and subsequent amplification of
the apoptosis signal via the mitochondrial pathway, our own
results and those by others demonstrate that Bim is also an
essential component of this pathway. Absence of Bim almost
completely abrogated anti-Fas antibody-induced hepatitis,
and synergized with lack of Bid in protecting from TNF-a-
mediated liver damage.9,13 Similarly, we find here that Bim is
an important component of the APAP-initiated hepatotoxic
signaling pathway.
Although we demonstrate here also an important amplifying
role of TRAIL in APAP-induced hepatocyte death in vitro and
liver damage in vivo, our results are not fully conclusive as
how TRAIL is involved in these processes. Clearly, we failed
to find strong evidence that TRAIL signaling may be involved
in the induction of Bim expression. In general, TRAIL did either
not induce Bim expression or was only a weak trigger. Thus,
TRAIL may directly or indirectly contribute to APAP-induced
Bim expression depending on varying circumstances. Ampli-
fication of the death signal in vivo and associated hepatocyte
death by TRAIL may enhance inflammatory responses, which
could further contribute to induction of Bim expression. Our
previous results on Fas-induced hepatocyte death rather
suggest, however, that TRAIL-induced signaling pathways
may be more critical for the activation of Bim by phosphoryla-
tion. For instance, absence of TRAIL led to reduced JNK
activation and Bim phosphorylation. Similarly, TRAIL may be
involved in activating APAP-induced Bim by JNK-mediated
phosphorylation.9 Disturbing in this hypothesis is the fact that
strong JNK activation, as measured by detection of phospho-
JNK, was much stronger in response to APAP than TRAIL
treatment. Clearly, though, TRAIL signaling can activate the
JNK pathway, and differential activation of JNK1 or JNK2
by APAP and TRAIL may result in APAP-mediated and
JNK-dependent Bim expression, or TRAIL-induced and
JNK-mediated Bim phosphorylation. Although our results
are not fully conclusive in this respect, they support a
synergistic role of TRAIL, JNK and Bim in APAP-induced
liver damage.
An open question is the cellular source of TRAIL in vivo.
TRAIL expression has been previously demonstrated in
various liver-homing leukocytes, including Kupffer cells and
NK cells and NKT cells.19,20 Interestingly, immune cells and
inflammation have been implicated in APAP-induced liver
damage, particularly as an amplifying element in this form of
liver disease. APAP-induced macrophage activation and
subsequent amplification of tissue damage has been shown
to involve toll-like receptor 9 and NALP3 inflammasome
activation.21 Similar processes may also result in TRAIL
expression in Kupffer cells and amplification of APAP-induced
liver damage.
Although our data support a role of the TRAIL-JNK-Bim axis
in a rather apoptotic form of cell death in response to APAP,
APAP-induced hepatocyte cell death clearly shows also more
necrosis-like features. Currently it is unknown whether
necrosis and apoptosis represent two independent events,
whether apoptosis occurs in some cells and necrosis in
others, or whether the two pathway are intimately linked.
Although the absence of TRAIL and Bim likely has a strong
inhibitory effect on the apoptosis pathway, it should not affect
APAP-induced necrosis if occurring independently. Histology
of APAP-treated liver tissue from both TRAIL and Bim
deficient mice revealed strongly reduced liver damage and
necrotic areas, suggesting that APAP-induced apoptosis and
necrosis depend on each other. Detailed examination,
however, also reveals that surviving hepatocytes still show
features of stressed cells, for example, strong vacuolization.
Thus, blocking apoptosis may strongly reduce tissue damage,
however, may not be sufficient to block APAP-induced cellular
damage.
Nevertheless, our present data illustrate that inhibition of
either TRAIL or Bim results in a substantial amelioration of
disease pathology. Thus, selective inhibition of this signal
transduction pathway may represent a novel and successful
therapy in the treatment of APAP overdose-associated liver
damage. Current treatment of APAP poisoning involved
administration of N-acetylcysteine, which helps to build up
cellular glutathione levels and thus to detoxify NAPQI. This
treatment targets, however, not the cell death-inducing
pathway per se but seeks to remove the trigger of tissue
destruction, which may be often too late. Targeting critical
signaling elements in APAP-induced liver cell death may thus
represent a more efficient strategy.
Materials and Methods
Cell and cell lines. HepG2 (a hepatoma cell line) and IHH were kindly provided
by JF Dufour (Institute for Clinical Pharmacology, Inselspital, University of Bern).
Cells were cultured in IMDM medium, containing 5% FCS, 1% L-glutamine and
0.1% gentamicin. Primary hHeps were isolated as described previously from the
liver tissue of consented patients undergoing liver surgery. Human hepatocytes
were enzymatically dissociated from human liver samples using a
two-step enzymatic microperfusion technique with collagenase and kept on ice in
suspension.22 Human hepatocytes were cultured in Williams E medium containing
10% FCS, 1% L-glutamine, 0.1% gentamicin, 0.01% insulin/aprotinin and 0.05%
transferrin.
Cell death assay (MTT). HepG2 and IHH were grown in logarithmic phase,
harvested and plated in 96-well flat bottom plates. Primary hHeps were directly
seeded into collagen-coated 96-well flat bottom plates. After overnight adherence,
medium was changed and cells were treated with increasing concentrations of
recombinant human TRAIL (untagged form, R&D Systems, Schonenbuch/Basel,
Switzerland) and APAP (paracetamol, Sigma-Aldrich, St. Louis, MO, USA) for 16 h.
Cell viability was then assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide MTT assay (Sigma-Aldrich) and normalized to untreated
controls.9
Annexin V staining. After different treatments, HepG2 and IHH cell death was
monitored by Annexin V-FITC staining (eBioscience, San Diego, CA, USA) at
different time points depending on the experiment. Briefly, the cells were harvested,
centrifuged and resuspended in 50 ml Annexin V binding buffer (10 mM Hepes pH
7.4, 150 mM NaCl, 5 mM KCl, 1 mM MgCl2 and 1.5 mM CaCl2) containing Annexin
V-FITC. The cells were stained for 10 min in the dark, washed two times with
Annexin V binding buffer, resuspended into 200 ml Annexin V binding buffer and
analyzed on a FACScan flow cytometer using Cell Quest software (Becton
Dickinson, Heidelberg, Germany). The percentage of Annexin V-FITC-positive cells
was then calculated using the Flow Jo software 8.7.3 (FlowJo LLC Software
package, Ashland, OR, USA).
Caspase activity assay (DEVDase activity). Cells were treated with
TRAIL and/or APAP as indicated, and harvested after 6 h. Cells were then washed
and lysed for 10 min on ice with 200 ml PBS containing 1% Triton X-100. After
centrifugation for 5 min at 16 000 g at 4 1C, supernatant was harvested and 50 ml
were mixed with 150 ml Hepes buffer (100 mM Hepes, pH 7.5, 20% glycerol, 0.5 mM
EDTA, 5 mM DTT) containing 100 mM Ac-DEVD-AFC (Alexis Biochemicals,
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San Diego, CA, USA). Reactions were incubated for 1 h at 371C, and enzymatic
activity was measured on a spectrofluorometer (400 nm excitation, 505 nm
emission). Background fluorescence was measured by incubating caspase
substrate with lysis buffer.
Western blot analysis. Cells were treated as indicated, before lysis in cell
lysis buffer containing 150 mM NaCl, 1% NP-40, 0.5% deoxycholic acid, 0.1% SDS
and 50 mM Tris, pH 7.4. Cell lysates were separated by electrophoresis and
transferred to nitrocellulose. JNK, phosphorylated JNK and Bim were detected by
incubation of membranes with the respective primary antibodies (anti-JNK and anti-
phospho JNK, Cell Signaling Technology, Allschwil, Switzerland; anti-Bim antibody
dilution, Sigma-Aldrich) and corresponding horseradish peroxidase–labelled
secondary antibodies. Signals were visualized by enhanced chemiluminescence
and detected in a Fujifilm LAS 4000 imaging system (Fujifilm Corporation, Akasaka,
Japan).
Quantitative PCR. Human and mouse Bim mRNA expression was detected by
quantitative RT-PCR as described earlier.16 Briefly, cells were lysed in TRI reagent
(Sigma-Aldrich) and RNA was isolated. RNA was DNase-treated (Promega,
Madison, WI, USA) and 2 mg of RNA were reverse transcribed using a high capacity
kit (Applied Biosystems, Rotkreuz Zug, Switzerland). Real-time PCR was performed
in an Applied Biosystems Real-time PCR 7500 machine using SYBR green and
Quantitec primer assays (QIAGEN, Hilden, Germany). GAPDH was used to
normalize Bim expression levels.
Bimpromoter assay. The murine bim p0.8 reporter was generated by cloning
0.8 kb upstream of the transcription start site of the murine bim gene (Genbank
AL805950) into the pGL2-basic plasmid (Promega). The two FOXO sites present in
bim p0.8 promoter construct (FOXO binding site 1 ggaaacaac-ggttcgaag; position
618 to 626 bp upstream of bim exon1; FOXO binding site 2 gtaaacac-
gtagtggc; position168 to175 bp) were modified by site-directed mutagenesis to
generate bim p0.8 (mut1, 2)-pGL2-basic luciferase reporter construct. Wild-type and
mutated bim reporter constructs, and b-galactosidase expression vector for
transfection control, were co-transfected into IHH cells using Amaxa Nuleofection kit
(Amaxa, Cologne, Germany). Cells were plated on a 10 cm plate for 1 day,
harvested and distributed on a 96-well flat bottom plate. Cells were then incubated
with increasing concentrations of buffer control, APAP (10 mM) or TRAIL (30 ng/ml)
for 6 h. In some experiments, cells were preincubated with different concentrations
of the JNK V Inhibitor (Calbiochem, Darmstadt, Germany). Cells were washed once
with PBS, and then cell lysates were prepared by adding lysis buffer directly to the
cells for 20 min at RT on a rocking table. Lysates were transferred to a V-bottom
plate and centrifuged for 10 min with 2000 g at RT. A total volume of 40 ml was
used for the reporter assay and 40ml for the b-galactosidase assay. Luciferase
activity was quantified using Orion Microplate Luminometer (Pforzheim, Germany).
In vivo experiments. After a 24 h fasting period, adult TRAIL-deficient
(TRAIL/), Bim-deficient (Bim/) mice and WT C57BL/6 mice were injected
i.p. with 400 ml PBS or 10 mg APAP (400 mg/kg body weight) dissolved in warm
PBS. Mice were killed at the indicated time points, and serum and liver samples
were collected. Liver samples were either snap-frozen in liquid nitrogen for
subsequent isolation of mRNA and proteins, or fixed in 4% paraformaldehyde in
PBS for paraffin embedding and histology. Serum AST levels were measured using
a commercially available kit (TECO Diagnostics, Anaheim, CA, USA). All animal
experiments were reviewed and approved by the Animal Experimentation Review
Board of the State of Bern.
Statistical analysis. Statistical differences were analyzed using unpaired two-
tailed Student’s t-test. P-valueso0.05 were considered significant.
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